Nectar Lifesciences financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹0.0cr−100.0% on Q1 FY26
Net profit
−₹15.4cr−₹63.2 cr in Q1 FY26
EBITDA margin
−1,91,031.0%−191009.0 pts on Q1 FY26
EPS
−₹0.79−₹2.82 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue0.0281−100.0%
EBITDA−27.7−61.9—
EBITDA margin−1,91,031.0%−22.1%−191009.0 pts
Profit before tax−24.6−96.8—
Net profit−15.4−63.2—
EPS−₹0.79−₹2.82—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹0.0 crNet profit₹−15.4 crNet margin−1,06,191.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
201————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
13.013.019.820.317.9
0.00.0582636754
188————
5.00.01,6731,6861,525
—−100.0%−0.7%+10.6%—
−89.2−60.7−26.515353.9
−1,779.9%—−1.6%9.1%3.5%
−89.7−61.0−88.892.4−5.2
−245−293−1145.0−24.2
−4,890.3%—−6.8%0.3%−1.6%
−₹12.61−₹15.08−₹5.85₹0.26−₹1.24
—−157.6%−2,376.1%+120.7%—
—−349169225134
—−12.3−43.8−29.4−30.1
−361−361126195104
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NECLIFE₹10.34

Nectar Lifesciences Limited

· Pharma & Health
₹ CrorePeersAAREYDRUGSNATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹201 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————200.9
- Cash, Equiv & ST Investments17.920.319.813.013.0
+ Total Debt753.8635.5582.00.00.0
Enterprise Value————187.9
Revenue1,524.61,685.61,673.10.05.0
Growth %, YoY—+10.6-0.7-100.0—
EBITDA53.9153.1-26.5-60.7-89.2
Margin %3.549.08-1.58—-1,779.89
EBIT-5.292.4-88.8-61.0-89.7
Net Income-24.25.0-113.7-292.9-245.1
Margin %-1.590.30-6.79—-4,890.30
EPS, Adj (current shares)-1.240.26-5.85-15.08-12.61
Growth %, YoY—+120.7-2,376.1-157.6—
Cash from Operations133.7224.7169.4-348.7—
Capital Expenditures-30.1-29.4-43.8-12.3—
Free Cash Flow103.6195.3125.6-361.0-361.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Nectar Lifesciences financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Nectar Lifesciences (NSE: NECLIFE) had a market capitalisation of ₹201 crore at the 29 October 2026 close (₹10.33 a share) and a price-to-book ratio of 0.34. In FY26 its consolidated net loss was ₹293 crore; in Q1 FY27 (April–June 2026) it was a loss of ₹15.4 crore. It had no borrowings on 31 March 2026. Promoters held 51.84% of the shares on 30 September 2026.

Share price used
₹10.33 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Nectar Lifesciences at a glance · consolidated

Market cap
₹201 Crat ₹10.33 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
0.34book value ₹29.97 a share
ROE (FY26)
−38.1%−26.8 pts vs FY25ROCE −7.5%
Debt to equity
0.00net cash ₹125 Cr
Promoter holding
51.84%unchanged vs 30 Jun 202630 September 2026
Net worth
₹582 Cr−39.1% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹361 Cr
EPS (FY26)
−₹13.40

Questions

What is the Nectar Lifesciences PE ratio today?

Nectar Lifesciences' PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q2 FY26 to Q1 FY27) was a loss of ₹245 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹201 crore at ₹10.33 a share.

What is the Nectar Lifesciences PB ratio (price to book value)?

Nectar Lifesciences' price-to-book (PB) ratio is 0.34 at the 29 October 2026 close: a market capitalisation of ₹201 crore divided by shareholders' equity (book value) of ₹582 crore on 31 March 2026. That is a book value of ₹29.97 per share against a share price of ₹10.33.

What is the Nectar Lifesciences ROE and ROCE?

In FY26, Nectar Lifesciences' return on equity (ROE) was −38.1% and its return on capital employed (ROCE) was −7.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −11.2% and ROCE −7.9%.

What is the Nectar Lifesciences market cap?

Nectar Lifesciences' market capitalisation was ₹201 crore at the 29 October 2026 close: 19.43 crore shares at ₹10.33 each.

Is Nectar Lifesciences debt free?

Yes. Nectar Lifesciences had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹125 crore of cash, bank balances and current investments.

What is the Nectar Lifesciences debt to equity ratio?

Nectar Lifesciences' debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹582 crore. A year earlier, on 31 March 2025, it was 0.61.

What is the Nectar Lifesciences net worth?

Nectar Lifesciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹582 crore on 31 March 2026, down 39.1% from ₹956 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹201 crore at the 29 October 2026 close.

What is the Nectar Lifesciences book value per share?

Nectar Lifesciences' book value per share was ₹29.97 on 31 March 2026: shareholders' equity of ₹582 crore divided by the 19.43 crore shares in issue. The share price at the 29 October 2026 close was ₹10.33.

What is the Nectar Lifesciences promoter holding?

Promoters held 51.84% of Nectar Lifesciences on 30 September 2026, unchanged from the previous quarter and up 6.93 percentage points from 44.91% a year earlier, according to the shareholding pattern filed with NSE.

What is the Nectar Lifesciences EPS?

Nectar Lifesciences' basic earnings per share (EPS) were −₹13.40 in FY26, against −₹5.07 in FY25.

What is the Nectar Lifesciences revenue and profit in FY26?

In FY26 (April 2025–March 2026), Nectar Lifesciences' consolidated net loss was ₹293 crore, wider than the loss of ₹114 crore in FY25.

When are the Nectar Lifesciences next results?

Nectar Lifesciences has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

What is the Nectar Lifesciences shareholding pattern?

On 30 September 2026, Nectar Lifesciences' shares were held by promoters 51.84%, foreign portfolio investors (FII/FPI) 0.50%, domestic institutions (DII) 3.90% and retail and other non-institutional investors 43.74%. Over the year, FII holding was down 0.12 percentage points from 0.62% and DII holding was up 3.81 percentage points from 0.09%.

How does Nectar Lifesciences compare with its peers?

On FY26 consolidated figures, against Aarey Drugs & Pharmaceuticals, Natural Capsules and Medicamen Biotech: Nectar Lifesciences' return on equity of −38.1% is the lowest of the four (Aarey Drugs & Pharmaceuticals 2.8%, Natural Capsules −7.5%, Medicamen Biotech 4.0%; peer average −0.3%).

Nectar Lifesciences vs Aarey Drugs & Pharmaceuticals: how do they compare?

In FY26, Nectar Lifesciences earned net profit of ₹293 crore on revenue of ₹0 lakh, against ₹4 crore on ₹472 crore for Aarey Drugs & Pharmaceuticals. At the 29 October 2026 close, Nectar Lifesciences' market capitalisation was ₹201 crore against ₹315 crore for Aarey Drugs & Pharmaceuticals.

What is the Nectar Lifesciences free cash flow?

In FY26, Nectar Lifesciences generated ₹349 crore of cash from operations and spent ₹12.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹361 crore. In FY25 it was ₹126 crore.

What are the Nectar Lifesciences latest quarterly results?

Nectar Lifesciences' latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net loss ₹15.4 crore, narrower than the loss of ₹63.2 crore in Q1 FY26; revenue from operations ₹1.5 lakh, down 100.0% year on year.

Where do these Nectar Lifesciences figures come from?

From Nectar Lifesciences' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.